Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, announced key organizational changes within its biologics business to further align its organization with customer demand for integrated and comprehensive, end-to-end biologics solutions.
The reorganization follows the company’s 2017 acquisition of Cook Pharmica LLC, and with it the addition of its 875,000-square-foot facility in Bloomington, IN to provide comprehensive biologics development, analytical services, and drug substance and drug product manufacturing.
Tedd Green, former President of Cook Pharmica, becomes senior vice president of Catalent Biologics, and will have responsibility for the entire biologics business. He will continue to report to Barry Littlejohns, president, Catalent Biologics and Specialty Drug Delivery, and will also act as a member of Catalent’s executive leadership team. Green will be based at the Bloomington facility.
Mike Riley becomes vice president and general Mmnager of Drug Substance and Bioanalytical services for Catalent Biologics. He will lead the company’s biologics manufacturing business, including its mammalian cell-line engineering and biomanufacturing capabilities, and its broad bioanalytical capabilities based at several sites across Catalent’s global network.
Cory Lewis will take on the new role of vice president and general manager of the Catalent Biologics Drug Product business, with a focus on successfully growing the Catalent Biologics drug product offerings both in the U.S. and in Europe.
In a further move, Ryan Hawkins has been appointed as general manager of the Bloomington site, having been instrumental to its success through his contributions and leadership over the last 10 years.
With the $950 million acquisition of Cook Pharmica, in October 2017, Catalent further strengthened its position in integrated biologics development, clinical and commercial-scale manufacturing, and finished product supply.
The additions also boost the company’s involvement in liquid and lyophilized sterile formulation and fill-finish across vials, prefilled syringes, auto-injectors, cartridges, and safety devices, and 2,500-liter biomanufacturing capacity to augment Catalent’s existing biologics infrastructure.
(Source: Catalent Pharma Solutions)